Karolinska University Hospital
Verified site
Solna, Sweden
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The trial involves individuals with classic congenital adrenal hyperplasia, a rare inherited condition in which the adrenal glands do not produce enough hormones, leading to hormone imbalance. The investigational medicine being studied is Asedebart, also known by the code name Lu AG13909. The drug is given as a solution for injection that is administered subcutaneous, meaning it is placed just under the skin.
The purpose of the study is to evaluate the safety and tolerability of long‑term treatment with Asedebart in participants with classic congenital adrenal hyperplasia. Safety is monitored by recording any side effects that appear during treatment. Blood samples are taken periodically to see how the medicine is processed in the body and how it changes hormone levels. The study also checks whether the immune system creates antibodies against the drug, which are called anti‑drug antibodies.
Participants receive the medication at regular intervals over a period of several years, with scheduled clinic visits for injections, blood draws, and routine health checks. The visits allow researchers to track hormone levels, adjust any other hormone medicines if needed, and observe any adverse events. The overall follow‑up continues until the planned end of the study.
The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.
6 criteria
14 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Solna, Sweden
Gothenburg, Sweden
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental medicine being tested in people with classic congenital adrenal hyperplasia. It is provided as a liquid that is injected under the skin. The trial is looking at how safe it is when used for a long time and whether patients can tolerate it well.
is the same investigational product but is given as a liquid that is infused into a vein. Like Asedebart, it is being studied in participants with congenital adrenal hyperplasia to see if it is safe and well‑tolerated over an extended period.
This medication is given as a subcutaneous injection in a liquid solution. It is still an experimental drug being studied in clinical trials and has not yet received market approval. It is being tested to treat classic congenital adrenal hyperplasia, a rare condition where the adrenal glands make too many hormones. It works by blocking a key enzyme that makes excess steroid hormones, placing it in the class of steroidogenesis inhibitors and it is designated as an orphan drug.
This medication is delivered intravenously as a solution for infusion. Like Asedebart, it is an investigational product that has not been approved for general medical use. It is also aimed at treating classic congenital adrenal hyperplasia. Its action is to inhibit the same hormone‑producing enzyme, classifying it as a steroidogenesis inhibitor and an orphan drug.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.